
    
      Primary objective is pulmonary function as assessed by FEV1 and secondary objectives are
      health related quality of life as assessed by the modified MRC dyspnea score and by the COPD
      assessment test, and survival at five years. 2000 patients will be enrolled in the study from
      approximately 200 referring centres in Germany. Patients will be followed up at 3, 6, and 12
      months, and then yearly up to 5 years. The study will observe normal clinical practice. No
      investigations beyond those performed in normal clinical practice will be required with the
      exception of two short questionnaires. Patients will only be enrolled in the study if they
      have provided informed written consent for their anonymised data to be used in the study.
      Zephyr Endobronchial Valve has CE mark and is fully reimbursed in Germany and will not be
      provided by the sponsor for this study but will be obtained through normal commercial
      channels in accordance with normal clinical practice.
    
  